J 2021

Enhancing cisplatin anticancer effectivity and migrastatic potential by modulation of molecular weight of oxidized dextran carrier

MUNSTER, L., Michaela FOJTŮ, M. MUCHOVA, F. LATECKA, S. KACEROVA et. al.

Basic information

Original name

Enhancing cisplatin anticancer effectivity and migrastatic potential by modulation of molecular weight of oxidized dextran carrier

Authors

MUNSTER, L., Michaela FOJTŮ (203 Czech Republic, belonging to the institution), M. MUCHOVA (203 Czech Republic), F. LATECKA (203 Czech Republic), S. KACEROVA (203 Czech Republic), Z. CAPAKOVA (203 Czech Republic), Tamara JURIŇÁKOVÁ (703 Slovakia, belonging to the institution), I. KURITKA (203 Czech Republic), Michal MASAŘÍK (203 Czech Republic, belonging to the institution) and J. VICHA (203 Czech Republic, guarantor)

Edition

Carbohydrate Polymers, Oxford, ELSEVIER SCI LTD, 2021, 0144-8617

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10401 Organic chemistry

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 10.723

RIV identification code

RIV/00216224:14110/21:00119604

Organization unit

Faculty of Medicine

UT WoS

000689229600012

Keywords in English

Drug-delivery; Dextran; Periodate oxidation; Molecular weight; Cisplatin; Carrier

Tags

International impact, Reviewed
Změněno: 24/1/2022 07:55, Mgr. Tereza Miškechová

Abstract

V originále

The molecular weight (M-w) of dextran derivatives, such as regioselectively oxidized dicarboxydextran (DXA), is greatly influencing their faith in an organism, which could be possibly used to improve anticancer drug delivery. Here we present a modified method of sulfonation-induced chain scission allowing direct and accurate control over the M-w of DXA without increasing its polydispersity. Prepared DXA derivatives (M-w = 10-185 kDa) have been conjugated to cisplatin and the M-w of the carrier found to have a significant impact on cisplatin release rates, in vitro cytotoxicity, and migrastatic potential. Conjugates with the high-M-w DXA showed particularly increased anticancer efficacy. The best conjugate was four times more effective against malignant prostatic cell lines than free cisplatin and significantly inhibited the ovarian cancer cell migration. This was traced to the characteristics of spontaneously formed cisplatin-crosslinked DXA nanogels influenced by M-w of DXA and amount of loaded cisplatin.

Links

GA19-16861S, research and development project
Name: Interakce biomateriálů s kmenovými buňkami v simulovaných in vivo podmínkách (Acronym: IBMSKB)
Investor: Czech Science Foundation
LM2018127, research and development project
Name: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1246/2020, interní kód MU
Name: Kardiovaskulární systém: od iontového kanálu k celotělovému modelu (Acronym: KAVASYKAMO)
Investor: Masaryk University
MUNI/A/1698/2020, interní kód MU
Name: Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí (Acronym: ComplexPF)
Investor: Masaryk University
MUNI/11/SUP/08/2020, interní kód MU
Name: Pokročilé 3D nádorové sféroidy pro terapeutický in vitro screening
Investor: Masaryk University